The HCV Drug Development Advisory Group (DrAG) is a unique forum that brings together representatives from the U.S. and European regulatory agencies, academia, patient advocates and the pharmaceutical industry to build consensus around drug development-related issues. This Q&A video series features the reflections of several DrAG members on the impact the group has had on HCV drug development.